324573-63-9

Upstream product

• 324573-56-0 4-methoxy-1-(3,4,5-trimethoxy-phenyl)-1H-furo[3,4-c]pyridin-3-one 

Downstream Products

• 324572-92-1 2-((2-methylpyridin-4-yl)methyl)-4-(3,4,5-trimethoxyphenyl)-8-((pyrimidin-2-yl)methoxy)-1,2-dihydro-1-oxo-2,7-naphthyridine-3-carboxylic acid methyl ester 
• 324572-80-7 8-chloro-2-(2-methyl-pyridin-4-ylmethyl)-1-oxo-4-(3,4,5-trimethoxy-phenyl)-1,2-dihydro-[2,7]naphthyridine-3-carboxylic acid methyl ester 
• 324572-77-2 8-methoxy-2-(2-methyl-pyridin-4-ylmethyl)-1-oxo-4-(3,4,5-trimethoxy-phenyl)-1,2-dihydro-[2,7]naphthyridine-3-carboxylic acid methyl ester 
• 324573-83-3 8-methoxy-1-oxo-4-(3,4,5-trimethoxy-phenyl)-1H-pyrano[3,4-c]pyridine-3-carboxylic acid 
• 324573-86-6 3-hydroxy-8-methoxy-1-oxo-4-(3,4,5-trimethoxy-phenyl)-3,4-dihydro-1H-pyrano[3,4-c]pyridine-3-carboxylic acid 

Relevant academic research and scientific papers

1,7- and 2,7-naphthyridine derivatives as potent and highly specific PDE5 inhibitors

Novel 1,7- and 2,7-naphthyridine derivatives, designed by the introduction of nitrogen atom into the phenyl ring of previously reported 4-aryl-1-isoquinolinone derivatives, were disclosed as a new structural class of potent and specific PDE5 inhibitors. Among them, 2,7-naphthyridine 4c showed potent PDE5 inhibition (IC50=0.23 nM) and one of the best PDE5 specificities against PDEs1-4,6 (>100,000-fold selective versus PDE1-4, 240-fold selective vs PDE6). This compound showed more potent relaxant effects on isolated rabbit corpus cavernosum (EC30=5.0 nM) than Sildenafil (EC30=8.7 nM). The compound 4c (T-0156) was selected for further biological and pharmacological evaluation of erectile dysfunction.